Woodward Diversified Capital LLC raised its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 2.9% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 6,196 shares of the medical research company’s stock after purchasing an additional 173 shares during the period. Amgen makes up 0.9% of Woodward Diversified Capital LLC’s portfolio, making the stock its 25th biggest holding. Woodward Diversified Capital LLC’s holdings in Amgen were worth $1,730,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also recently added to or reduced their stakes in the company. KPP Advisory Services LLC increased its holdings in shares of Amgen by 87.1% during the first quarter. KPP Advisory Services LLC now owns 5,833 shares of the medical research company’s stock worth $1,817,000 after purchasing an additional 2,716 shares during the period. Advisor Resource Council acquired a new stake in shares of Amgen during the 1st quarter worth $1,331,000. Trinity Legacy Partners LLC increased its position in shares of Amgen by 3.9% in the first quarter. Trinity Legacy Partners LLC now owns 16,132 shares of the medical research company’s stock worth $5,026,000 after purchasing an additional 612 shares during the period. DLK Investment Management LLC raised its stake in Amgen by 7.3% in the first quarter. DLK Investment Management LLC now owns 20,491 shares of the medical research company’s stock valued at $6,384,000 after purchasing an additional 1,387 shares in the last quarter. Finally, Founders Financial Alliance LLC lifted its position in Amgen by 2.7% during the first quarter. Founders Financial Alliance LLC now owns 1,577 shares of the medical research company’s stock worth $491,000 after purchasing an additional 42 shares during the period. Institutional investors own 76.50% of the company’s stock.
Wall Street Analyst Weigh In
A number of brokerages have issued reports on AMGN. William Blair reiterated an “outperform” rating on shares of Amgen in a research note on Tuesday, June 24th. Wall Street Zen lowered shares of Amgen from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Piper Sandler lifted their price objective on shares of Amgen from $328.00 to $342.00 and gave the company an “overweight” rating in a research note on Monday, August 25th. Cantor Fitzgerald restated a “neutral” rating and set a $305.00 target price on shares of Amgen in a research note on Tuesday, June 24th. Finally, Raymond James Financial began coverage on Amgen in a report on Wednesday, September 3rd. They issued a “market perform” rating on the stock. Seven analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Amgen currently has a consensus rating of “Hold” and an average price target of $309.70.
Insiders Place Their Bets
In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of the company’s stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total value of $376,286.33. Following the completion of the transaction, the senior vice president directly owned 7,209 shares in the company, valued at approximately $2,141,000.91. This represents a 14.95% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.76% of the stock is owned by insiders.
Amgen Trading Up 5.8%
NASDAQ AMGN opened at $298.50 on Thursday. The company has a market cap of $160.70 billion, a price-to-earnings ratio of 24.41, a price-to-earnings-growth ratio of 2.45 and a beta of 0.49. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $335.88. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24. The business’s fifty day moving average is $287.74 and its 200 day moving average is $288.64.
Amgen (NASDAQ:AMGN – Get Free Report) last posted its earnings results on Tuesday, August 5th. The medical research company reported $6.02 EPS for the quarter, beating the consensus estimate of $5.28 by $0.74. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The firm had revenue of $9.18 billion during the quarter, compared to the consensus estimate of $8.86 billion. During the same period last year, the company earned $4.97 earnings per share. The business’s quarterly revenue was up 9.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. As a group, sell-side analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.
Amgen Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Friday, September 12th. Shareholders of record on Friday, August 22nd were issued a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 3.2%. The ex-dividend date of this dividend was Friday, August 22nd. Amgen’s payout ratio is presently 77.84%.
Amgen Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Further Reading
- Five stocks we like better than Amgen
- There Are Different Types of Stock To Invest In
- Datavault AI: The New AI Contender Backed by Big Funding
- What Are Dividend Challengers?
- CoreWeave: Why the New King of AI Infrastructure Has Room to Run
- Conference Calls and Individual Investors
- Top 3 Dividend Achievers for October: High Yields, Growth Ahead
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.